secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001493152-23-022862
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx announces positive interim Phase III data: RenovoGem delays progression by 8 months in pancreatic cancer
--------------------------------------------------------------------------------

- Interim Phase III data show RenovoGem delays cancer progression by 8 months in locally advanced pancreatic cancer.
- RenovoRx issued press release on June 29, 2023 detailing positive interim results from ongoing trial.
- RenovoGem is delivered via RenovoRx's proprietary targeted therapy platform for difficult-to-treat cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223022862/0001493152-23-022862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315223022862/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-022862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer